drugset / Trial / NCT06329908
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
Timeline
- Start
- 2023-09-27
- Primary completion
- 2024-09-30
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LG002 | Vaccine | 1.5e+07 cells | Subcutaneous |